Formation of cytotoxic transthyretin is not dependent on inter-molecular disulphide bridges commonly found within the amyloid form

References

• Bellotti V, Nuvolone M, Giorgetti S, Obici L, Palladini G, Russo P, Lavatelli F, Perfetti V, Merlini G. The workings of the amyloid diseases. Ann Med 2007; 39: 200–207
   PubMed Web of Science ®Google Scholar
• Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005; 62: 1057–1062
   PubMed Web of Science ®Google Scholar
• Blake C, Geisow M, Oatley S, Rérat B, Rérat C. Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A. J Mol Biol 1978; 121: 339–356
   PubMed Web of Science ®Google Scholar
• Goodman D. Retinol-binding protein, prealbumin, and vitamin A transport. Prog Clin Biol Res 1976; 5: 313–330
   PubMedGoogle Scholar
• Dickson P, Aldred A, Marley P, Bannister D, Schreiber G. Rat choroid plexus specializes in the synthesis and the secretion of transthyretin (prealbumin). Regulation of transthyretin synthesis in choroid plexus is independent from that in liver. J Biol Chem 1986; 261: 3475–3478
   PubMed Web of Science ®Google Scholar
• Buxbaum J N, Ye Z, Reixach N, Friske L, Levy C, Das P, Golde T, Masliah E, Roberts A R, Bartfai T. Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Abeta toxicity. Proc Natl Acad Sci USA 2008; 105: 2681–2686
   PubMed Web of Science ®Google Scholar
• Colon W, Kelly J. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 1992; 31: 8654–8660
   PubMed Web of Science ®Google Scholar
• Quintas A, Saraiva M, Brito R. The tetrameric protein transthyretin dissociates to a non-native monomer in solution. A novel model for amyloidogenesis. J Biol Chem 1999; 274: 32943–32949
   PubMed Web of Science ®Google Scholar
• Sekijima Y, Wiseman R, Matteson J, Hammarström P, Miller S, Sawkar A, Balch W, Kelly J. The biological and chemical basis for tissue-selective amyloid disease. Cell 2005; 121: 73–85
   PubMed Web of Science ®Google Scholar
• Benson M, Kincaid J. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007; 36: 411–423
   PubMed Web of Science ®Google Scholar
• Westermark P, Sletten K, Johansson B, Cornwell G R. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA 1990; 87: 2843–2845
   PubMed Web of Science ®Google Scholar
• Ferreira S, Vieira M, De Felice F. Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB Life 2007; 59: 332–345
   PubMed Web of Science ®Google Scholar
• Lambert M P, Barlow A K, Chromy B A, Edwards C, Freed R, Liosatos M, Morgan T E, Rozovsky I, Trommer B, Viola K L, Wals P, Zhang C, Finch C E, Krafft G A, Klein W L. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998; 95: 6448–6453
   PubMed Web of Science ®Google Scholar
• Reixach N, Deechongkit S, Jiang X, Kelly J, Buxbaum J. Tissue damage in the amyloidoses: transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci USA 2004; 101: 2817–2822
   PubMed Web of Science ®Google Scholar
• Sousa M, Cardoso I, Fernandes R, Guimarães A, Saraiva M. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol 2001; 159: 1993–2000
   PubMed Web of Science ®Google Scholar
• Sousa M, Fernandes R, Palha J, Taboada A, Vieira P, Saraiva M. Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro. Am J Pathol 2002; 161: 1935–1948
   PubMed Web of Science ®Google Scholar
• Pokrzywa M, Dacklin I, Hultmark D, Lundgren E. Misfolded transthyretin causes behavioral changes in a Drosophila model for transthyretin-associated amyloidosis. Eur J Neurosci 2007; 26: 913–924
   PubMed Web of Science ®Google Scholar
• Shimada K, Maeda S, Murakami T, Nishiguchi S, Tashiro F, Yi S, Wakasugi S, Takahashi K, Yamamura K. Transgenic mouse model of familial amyloidotic polyneuropathy. Mol Biol Med 1989; 6: 333–343
   PubMedGoogle Scholar
• Takaoka Y, Ohta M, Miyakawa K, Nakamura O, Suzuki M, Takahashi K, Yamamura K, Sakaki Y. Cysteine 10 is a key residue in amyloidogenesis of human transthyretin Val30Met. Am J Pathol 2004; 164: 337–345
   PubMed Web of Science ®Google Scholar
• Thylén C, Wahlqvist J, Haettner E, Sandgren O, Holmgren G, Lundgren E. Modifications of transthyretin in amyloid fibrils: analysis of amyloid from homozygous and heterozygous individuals with the Met30 mutation. EMBO J 1993; 12: 743–748
   PubMed Web of Science ®Google Scholar
• Goldsteins G, Andersson K, Olofsson A, Dacklin I, Edvinsson A, Baranov V, Sandgren O, Thylén C, Hammarstrom S, Lundgren E. Characterization of two highly amyloidogenic mutants of transthyretin. Biochemistry 1997; 36: 5346–5352
   PubMed Web of Science ®Google Scholar
• Serpell L C, Goldsteins G, Dacklin I, Lundgren E, Blake C CF. The “edge-strand” hypothesis: prediction and test of a mutational “hot-spot” on the transthyretin molecule associated with FAP amyloidogenesis. Amyloid 1996; 3: 75–85
   Web of Science ®Google Scholar
• White J, Kelly J. Support for the multigenic hypothesis of amyloidosis: the binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro. Proc Natl Acad Sci USA 2001; 98: 13019–13024
   PubMed Web of Science ®Google Scholar
• O'Brien J, Wilson I, Orton T, Pognan F. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 2000; 267: 5421–5426
   PubMedGoogle Scholar
• Hou X, Parkington H, Coleman H, Mechler A, Martin L, Aguilar M, Small D. Transthyretin oligomers induce calcium influx via voltage-gated calcium channels. J Neurochem 2007; 100: 446–457
   PubMedGoogle Scholar
• Teixeira P, Cerca F, Santos S, Saraiva M. Endoplasmic reticulum stress associated with extracellular aggregates. Evidence from transthyretin deposition in familial amyloid polyneuropathy. J Biol Chem 2006; 281: 21998–22003
   PubMedGoogle Scholar
• McCutchen S, Lai Z, Miroy G, Kelly J, Colón W. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. Biochemistry 1995; 34: 13527–13536
   PubMed Web of Science ®Google Scholar
• Sebastião M, Lamzin V, Saraiva M, Damas A. Transthyretin stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution. J Mol Biol 2001; 306: 733–744
   PubMed Web of Science ®Google Scholar
• Alves I, Altland K, Almeida M, Winter P, Saraiva M. Screening and biochemical characterization of transthyretin variants in the Portuguese population. Hum Mutat 1997; 9: 226–233
   PubMed Web of Science ®Google Scholar
• Hammarström P, Wiseman R, Powers E, Kelly J. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 2003; 299: 713–716
   PubMed Web of Science ®Google Scholar
• Munro S, Lim C, Hall J, Barlow J, Craik D, Topliss D, Stockigt J. Drug competition for thyroxine binding to transthyretin (prealbumin): comparison with effects on thyroxine-binding globulin. J Clin Endocrinol Metab 1989; 68: 1141–1147
   PubMed Web of Science ®Google Scholar
• Serag A, Altenbach C, Gingery M, Hubbell W, Yeates T. Identification of a subunit interface in transthyretin amyloid fibrils: evidence for self-assembly from oligomeric building blocks. Biochemistry 2001; 40: 9089–9096
   PubMed Web of Science ®Google Scholar
• Olofsson A, Ippel J, Wijmenga S, Lundgren E, Ohman A. Probing solvent accessibility of transthyretin amyloid by solution NMR spectroscopy. J Biol Chem 2004; 279: 5699–5707
   PubMedGoogle Scholar
• Zhang Q, Kelly J. Cys-10 mixed disulfide modifications exacerbate transthyretin familial variant amyloidogenicity: a likely explanation for variable clinical expression of amyloidosis and the lack of pathology in C10S/V30M transgenic mice. Biochemistry 2005; 44: 9079–9085
   PubMedGoogle Scholar
• Altland K, Winter P. Potential treatment of transthyretin-type amyloidoses by sulfite. Neurogenetics 1999; 2: 183–188
   PubMed Web of Science ®Google Scholar
• Zhang Q, Kelly J. Cys10 mixed disulfides make transthyretin more amyloidogenic under mildly acidic conditions. Biochemistry 2003; 42: 8756–8761
   PubMedGoogle Scholar